TSX
TSX company profile
Latest price
As of — · Market data by Massive
Market cap
—
Volume
—
Previous close
—
Day range
—
Listed
—
Coverage
52 articles
Price performance
Recent trading
Newsroom
Latest TSX coverage
Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – March 31, 2023 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Highlights · Generated revenue of $1.45 million in the fourth quarter of 2022 (91% growth against the fourth
Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – November 10, 2022 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights ● Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to th
Neovasc to Report Third Quarter Financial Results on November 10, 2022
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – October 27, 2022 – Neovasc Inc. (NASDAQ , TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to
Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – August 11, 2022 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Generated revenues of $818,000, a quarterly record and a year-over-year increase of 29% over the second quarter of
Neovasc to Report Second Quarter Financial Results on August 11, 2022
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – July 28, 2022 – Neovasc Inc. (NASDAQ , TSX : NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review th
Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – June 08, 2022 – Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 Sidoti & Co. Summer Small Cap Virtual Investor Conference to be held June 15-16, 2022. Neovasc’s Chief Operating Officer, Bill Little,
Neovasc to Participate in H.C. Wainwright Global Investment Conference
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – May 23, 2022 – Neovasc, Inc. (Neovasc or the Company) (NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. Fred Colen, Neovasc’s President and Chief Executive Officer, will be pr
Neovasc to Report First Quarter Financial Results on May 12, 2022
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – April 29, 2022 – Neovasc Inc. (NASDAQ , TSX : NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review th
Neovasc Comments on European Heart Journal Publication
[ad_1] Report demonstrates objective improvements in patients suffering from microvascular dysfunction VANCOUVER and MINNEAPOLIS – (NewMediaWire) – April 28, 2022 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the European Heart Journal has published an article entitled, “Impact of the Coronary Sinus R
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders
[ad_1] VANCOUVER, BC – (NewMediaWire) – April 13, 2022 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on April 12, 2022 in Vancouver, B.C. (the “Meeting”). At the Meeting, the shareholders ...
Neovasc Announces Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – March 10, 2022 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2021. Highlights Achieved record revenue in Q4 of $759,000, an increase of 48% over the same period in 2020 Achieved record rev
Neovasc Announces German Reimbursement Renewal and Commercial Progress
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – February 08, 2022 – Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 de
Neovasc to Participate in H.C. Wainwright BIOCONNECT Virtual Conference
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – January 06, 2022 – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022. A recorded presentation by Fred Colen, Neovasc’s Chief
Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance
[ad_1] Neovasc Granted Additional 180 Calendar Day Grace Period for Nasdaq Bid Price Compliance VANCOUVER and MINNEAPOLIS – (NewMediaWire) – November 24, 2021 – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Com
The National Institute for Health and Care Excellence of The United Kingdom Provides Positive Guidance for Neovasc Reducer System
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – November 24, 2021 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the United Kingdom’s Interventional Procedures Programme at the National Institute for Health and Care Excellence (“NICE”) has issued guidance supporting the implantation of the Neovasc R
Neovasc Reducer Featured in Polish Heart Journal
[ad_1] Publication Highlights Device Success in Chronic Total Occlusions of the Right Coronary Artery VANCOUVER and MINNEAPOLIS – (NewMediaWire) – October 21, 2021 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer™ (“Reducer”) is featured in an article published in the latest issue of t
Neovasc to Participate in 2021 Benzinga Healthcare Small Cap Conference
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – September 23, 2021 – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 2021 Benzinga Healthcare Small Cap Conference to be held September 29-30, 2021. Bill Little, Neovasc’s Chief Operating Officer, will giv
Neovasc Announces FDA Approval of COSIRA-II Clinical Trial
[ad_1] Company on Schedule to Commence Trial Late This Year VANCOUVER and MINNEAPOLIS – (NewMediaWire) – September 16, 2021 – Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received FDA approval for the Investigational Device Exemption (“IDE”) regarding the COSIRA-II IDE Clinical Trial. Following
Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – August 30, 2021 – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 23rd Annual H.C. Wainwright Global Investment Conference to be held September 13-15, 2021. A pre-recorded company presentation will be avail
Neovasc Announces Second Quarter 2021 Financial Results
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – August 10, 2021 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the second quarter ended June 30, 2021. Second Quarter Highlights Generated revenue of approximately $633,000 in the quarter, up 123% from the same period in 2020, and a
Largest Real-World Registry Supporting Neovasc Reducer(TM) Safety and Efficacy Outcomes Published in International Journal of Cardiology
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – June 18, 2021 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study” in the International Journal of Cardiology.
NewMediaWire | Neovasc Provides Corporate Update
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – June 10, 2021 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its cash runway well into 2024
Neovasc Provides Update on German Litigation
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – May 20, 2021 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) reported today that the Higher Regional Court in Munich, Germany has upheld the first instance judgment of the Regional Court Munich of June 16, 2017, in which the court had found that Edwards Lifes
Neovasc to Sponsor Symposium on Reducer at EuroPCR
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – May 13, 2021 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that it will sponsor a symposium presenting the latest long-term clinical data on the Reducer™ (“Reducer”), highlighting its easy integration into current cardiovascular and microvascular disease t
Neovasc Announces First Patient Enrollment in COSIMA Trial
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – May 10, 2021 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled in the COronarySInus Reducer for the Treatment of Refractory MicrovascularAngina (“COSIMA”) trial. The enrollment occurred at University Hospital, Mainz, Ge
Neovasc Announces First Quarter 2021 Financial Results
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – May 06, 2021 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the first quarter ended March 31, 2021. First Quarter Highlights Generated revenue of $451,794 in the quarter as Neovasc Reducer™ implants rebounded after being suppressed fo
Neovasc Provides Tiara TA Update
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – April 16, 2021 – Neovasc Inc.("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced that the Tiara Transapical system (“Tiara TA”) will be unable to receive a European CE mark under the current Medical Device Directive regulations (“MDD”) ending on May 26, 2021. The Company is c
Neovasc Announces Fourth Quarter and Fiscal Year 2020 Financial Results
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – March 11, 2021 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter Highlights Generated revenue of $514,000 in the quarter and $1.96 million for the full year as Re
Neovasc to Participate in 2021 H.C. Wainwright Global Life Sciences Conference
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – March 03, 2021 – Neovasc Inc. (NASDAQ, TSX: NVCN), today announced that company management will be participating in the 2021 H.C. Wainwright Global Life Sciences Conference that is scheduled to take place March 9-10, 2021. A recorded presentation by Bill Little, Neovasc’s C
Neovasc Comments on Journal of the American Heart Association Publication
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – February 05, 2021 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the Journal of the American Heart Association has published an article entitled, “Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina”. The prestigio
American Medical Association Issues New CPT Code for Neovasc Reducer Procedure
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – January 29, 2021 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT®) Category III Code for transcatheter implantation of a coronary sinus reduction device. The co
Neovasc Responds To FDA Not-Approvable Letter Regarding Neovasc Reducer
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – January 15, 2021 – Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received a “not-approvable” letter from U.S. Food & Drug Administration (FDA) regarding its PMA submission for the Neovasc Reducer™ (Reducer). Fred Colen, Neovasc CEO, said, “Whil
Neovasc Announces Participation in H.C. Wainwright BioConnect 2021 Virtual Conference
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – January 04, 2021 – Neovasc Inc. (Nasdaq, TSX: NVCN), today announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference, which takes place January 11-14, 2021. Neovasc President and Chief Executive Officer Fred Colen, Chief Operating Officer Bi
Neovasc Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – December 14, 2020 – Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with th
Neovasc Announces Closing of US$6.1 Million Registered Direct Offering Priced At-the-Market
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – December 10, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules of an agg
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – December 10, 2020 – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX:NVCN), announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with t
Neovasc Announces Participation in Noble Capital Markets Virtual Road Show Series
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – December 01, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for December 8, 2020. The virtual road show will feature a cor
Mansfield-Martin Exploration Mining, Inc. Announces Joint Venture and Earn-In Agreement With Tarku Resources
[ad_1] Companies’ plans include development of Tombstone Mining District Properties Tombstone, AZ – (NewMediaWire) – October 22, 2020 – Mansfield-Martin Exploration Mining, Inc. (MMEM) announced today that it has entered into a joint venture and earn-in agreement with Tarku Resources, Ltd. (TSX.V: TKU). The parties’ agr
Neovasc to Participate in H.C. Wainwright & Co. 22nd Annual Global Investment Conference
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – September 08, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today annou
Neovasc Inc. Reports Results of Annual General Meeting of Shareholders
[ad_1] Vancouver, BC, Canada – (NewMediaWire) – September 3, 2020 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on September 3, 2020 in Vancouver, B.C. (the “Meeting”). At the Meeting, the shareholders o
Neovasc Announces Second Quarter Financial Results
[ad_1] VANCOUVER and MINNEAPOLIS – (NewMediaWire) – August 06, 2020 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today rep
5 of Today’s Best Performing Canadian L.P. Stocks – January 3, 2018
[ad_1] Out of over 116 licensed producers of hashish beneath Health Canada’s Access to Cannabis for Medical Purposes Regulations, a big portion of them are publicly traded or are owned by a publicly traded firm. Out of 40 completely different publicly traded Canadian L.P. shares that we monitor throughout the TSX, TSXV, CSE, and the ...
5 of Today’s Best Performing Canadian L.P. Stocks – December 31, 2018
[ad_1] Out of over 116 licensed producers of hashish underneath Health Canada’s Access to Cannabis for Medical Purposes Regulations, a big portion of them are publicly traded or are owned by a publicly traded firm. Out of 40 completely different publicly traded Canadian L.P. shares that we monitor throughout the TSX, TSXV, CSE, and the ...
5 of Today’s Best Performing Canadian L.P. Stocks – December 28, 2018
[ad_1] Out of over 116 licensed producers of hashish below Health Canada’s Access to Cannabis for Medical Purposes Regulations, a big portion of them are publicly traded or are owned by a publicly traded firm. Out of 40 totally different publicly traded Canadian L.P. shares that we observe throughout the TSX, TSXV, CSE, and the ...
MediPharm Labs Announces Addition to Horizons Marijuana Life Sciences Index ETF
[ad_1] MediPharm Labs Corp. (TSXV:LABS) (the “Company” or “MediPharm Labs”), a specialised, analysis pushed hashish extraction enterprise licensed below the Cannabis Act, is happy to announce its addition to the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) (“HMMJ” or “ETF”). MediPharm Labs Corp. (TSXV:LABS) (the “Company” or “MediPharm Labs”), a spe
Canada stocks higher at close of trade; S&P/TSX Composite up 0.43% By Investing.com
[ad_1] © Reuters. Canada stocks higher at close of commerce; S&P/TSX Composite up 0.43% Investing.com – Canada stocks have been higher after the close on Friday, as positive factors within the , and sectors led shares higher. At the close in Toronto, the added 0.43%. The greatest performers of the session on the have been ...
5 of Today’s Best Performing Canadian L.P. Stocks – December 26, 2018
[ad_1] Out of over 116 licensed producers of hashish beneath Health Canada’s Access to Cannabis for Medical Purposes Regulations, a big portion of them are publicly traded or are owned by a publicly traded firm. Out of 40 completely different publicly traded Canadian L.P. shares that we observe throughout the TSX, TSXV, CSE, and the ...
HEXO Corp. Files Application to List on the NYSE
[ad_1] HEXO Corp. (TSX:HEXO) to comply with Aurora and Aphria to the NYSE… The publish HEXO Corp. Files Application to List on the NYSE appeared first on The Daily Marijuana Observer. [ad_2] Source link
5 of Today’s Best Performing Canadian L.P. Stocks – December 19, 2018
[ad_1] Out of over 116 licensed producers of hashish below Health Canada’s Access to Cannabis for Medical Purposes Regulations, a big portion of them are publicly traded or are owned by a publicly traded firm. Out of 40 totally different publicly traded Canadian L.P. shares that we monitor throughout the TSX, TSXV, CSE, and the ...
Sienna Announces December Dividend Toronto Stock Exchange:SIA.TO
[ad_1] MARKHAM, Ontario, Dec. 14, 2018 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) at the moment introduced a dividend of $0.0765 per frequent share of the Company (every, a “Common Share”) for the month of December 2018, representing $0.918 per Common Share on an annualized foundation. The dividend can ...
The Green Organic Dutchman Launches New Website
[ad_1] Toronto, ON — December 14, 2018 — /D.M.O. Newswire/ — The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX: TGOD) (US: TGODF) is happy to announce the launch of its model new experiential affected person and shopper web site centered on delivering the best possible on-line expertise within the trade. The results ...
Extendicare Announces December 2018 Dividend of C$0.04 per Share Toronto Stock Exchange:EXE
[ad_1] MARKHAM, Ontario, Dec. 13, 2018 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) introduced that it has declared a money dividend of C$0.04 per frequent share of the Company (the “Common Share”) for the month of December 2018, which is payable on January 15, 2019 to shareholders of file on the ...